Mohamed Ahmed
A5101813694- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Viral-associated cancers and disorders
- Chronic Myeloid Leukemia Treatments
- Sarcoma Diagnosis and Treatment
- Cardiac tumors and thrombi
- Biomedical Ethics and Regulation
- Gastrointestinal Tumor Research and Treatment
- Ovarian cancer diagnosis and treatment
- CRISPR and Genetic Engineering
- Adenosine and Purinergic Signaling
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Cancer-related molecular mechanisms research
- Cutaneous lymphoproliferative disorders research
- Advanced MRI Techniques and Applications
- Clostridium difficile and Clostridium perfringens research
- Acute Myeloid Leukemia Research
- Multiple and Secondary Primary Cancers
- Salivary Gland Tumors Diagnosis and Treatment
- Palliative Care and End-of-Life Issues
Cedars-Sinai Medical Center
2023-2025
Bay Medical Center
2024
The University of Texas MD Anderson Cancer Center
2014-2020
Johns Hopkins University
2009
We report our experience with 129 cases of double hit lymphoma (DHL), defined as B-cell translocations and/or extra signals involving MYC plus BCL2 BCL6. All were reviewed for histopathological classification. Median age was 62 years (range, 18-85), 84% patients had advanced-stage disease, and 87% an International Prognostic Index score ≥2. Fourteen (11%) a history low-grade follicular lymphoma. translocation present in 81%, 25% patients. IGH-BCL2 12% Two-year event-free survival (EFS) rates...
BACKGROUND The number of elderly patients with diffuse large B‐cell lymphoma (DLBCL) in our aging society continues to rise, although the optimal management very DLBCL is unknown. METHODS This study evaluated 207 who were 80 years old or older at diagnosis from 2002 2014 University Texas MD Anderson Cancer Center. Analyzed features included clinical characteristics, treatment outcomes, and tolerability therapy. Cox proportional hazards models examined relations between regimen survival....
Excellent outcomes obtained after infusional dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (R-EPOCH) alone have led some to question the role of consolidative radiation therapy (RT) in treatment primary mediastinal B cell lymphoma (PMBL). We reviewed patients treated with 1 3 rituximab-containing regimens (cyclophosphamide, prednisone [R-CHOP]; hyperfractionated doxorubicin dexamethasone [R-HCVAD], or R-EPOCH) without RT. also evaluated...
The impact of pre-treatment maximum standardized uptake value (SUVmax) on the outcome follicular lymphoma (FL) following specific frontline regimens has not been explored. We performed a retrospective analysis 346 patients with advanced stage without histological evidence transformation, and analyzed SUVmax after therapy. Fifty-two (15%) had >18, large lymph node ≥6 cm was only factor associating >18 multivariate (odds ratio 2.7, 95% confidence interval [CI]: 1.3-5.3, P=0.006). complete...
On the basis of results ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory (R/R) B-cell ALL (B-ALL). We report outcomes patients treated brexu-cel as standard therapy.
Abstract Menin is a scaffolding protein that can act as either tumor suppressor or oncogene depending on cell context. In MLL rearranged (MLLr) leukemia, menin functions an and small molecule inhibitor of was recently FDA approved for MLLr leukemia therapy (Revumenib, Syndax). We previously showed than promotes tumorigenicity Ewing sarcoma (EwS). the current work we studied knockout (MEN1-KO) VTP50469 (preclinical precursor to Revumenib) treated EwS cells test hypothesis inhibition could be...
Relapsed/Refractory (r/r) B-cell acute lymphoblastic leukemia patients with central nervous system involvement (CNS B-ALL) have poor outcomes and were frequently excluded from CD19-targeting chimeric antigen receptor T-cell (CAR T-cell) clinical trials. The efficacy safety of brexucabtagene autoleucel (brexu-cel) in adults r/r B-ALL was established by the ZUMA-3 trial, which advanced or symptomatic CNS involvement. In this retrospective multicenter analysis, we investigated brexu-cel...
7001 Background: In October 2021, brexucabtagene autoleucel (brexu-cel) became the first CAR-T cell therapy to receive FDA approval for adults (≥18 yrs) with relapsed/refractory (r/r) B-ALL. Approval was based on Phase II results of ZUMA-3, a single-arm, open-label, multicenter trial which reported 55 treated patients CR/CRi achieved in 71%; cytokine release syndrome (CRS) and neurologic toxicities occurred 89% (grade 3-4, 24%) 60% 25%), respectively. Here, we report outcomes 76 r/r B-ALL...
The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis 189 patients relapsed/refractory ALL treated brexu-cel. Over half the received InO before brexu-cel (InO exposed). InO-exposed were more heavily pretreated (P = .02) and frequently had active marrow disease apheresis .03). Response rate toxicity profile after comparable...
7516 Background: Patients with relapsed/refractory DLBCL have heterogeneous outcomes to subsequent therapy. The subgroup of these patients refractory disease (r-DLBCL) a worse prognosis. A multi-cohort study, SCHOLAR-1 (Retrospective Non-Hodgkin Lymphoma Research) was performed evaluate for r-DLBCL and serve as benchmark future clinical trials in this population. Methods: Eligible subjects had defined progressive (PD) or stable (SD) best response chemotherapy (duration SD <12 mos at least 4...
Introduction: The ibrutinib–rituximab combination produced durable responses in 88% of relapsed/refractory mantle cell lymphoma (MCL) patients, providing a “Window” opportunity to use chemotherapy-free induction with ibrutinib-rituximab followed by fewer cycles chemo-immunotherapy young, fit patients newly diagnosed MCL. Methods: Enrollment began June 2015 for Phase II single-center clinical trial consisting phase treatment (Part 1) until best response, shortened intense course 2) among MCL...
In 2 randomized phase 3 trials BR resulted in longer progression-free survival (PFS) than frontline R-CHOP patients with indolent and mantle cell lymphoma. However, subset analyses of follicular lymphoma (FL), the results were incongruent. We conducted a retrospective matched-pair analysis to compare outcome advanced stage FL, receiving (N = 73) or 73), matched by age, gender, stage, FL International Prognostic Index score. On multivariable analysis, baseline maximum standardized uptake...